Noam Frey, MD, MBA
Noam spent over 18 years excelling in Medical Affairs roles across the industry.
​
He started his career as a Medical Science Liaison and part of the medical team at ICOS Corporation where he participated in the launch of Cialis® in primary care and urology. He then supported the launch of Vyvanse® for ADHD at Shire Pharmaceuticals. Following completion of his MBA, Noam joined Actelion to lead the medical team of Tracleer®; the world-leading treatment for Pulmonary Arterial Hypertension (PAH), an orphan disease of the cardiovascular system.
He was then recruited to lead the launch preparations activities of bapineuzumab, a monoclonal antibody investigated for the treatment of Alzheimer's Disease. He headed the medical affairs group at Janssen Alzheimer Immunotherapy, a Johnson and Johnson company and was part of the J&J-Pfizer alliance medical management team.
After the failure of bapineuzumab to demonstrate efficacy in Phase III studies, Noam took on to build the North American Medical Affairs organization at InterMune, Inc. Noam got the company ready for the launch of Esbriet® in the US and was integral in the integration of his department into Roche-Genentech after the company was acquired. until recently Noam was the Vice President, Medical Affairs and Pharmacovigilance at Jazz Pharmaceuticals where he oversaw the launches of Defitelio® and Vyxeos® in the hemato-oncology space and Sunosi® a wake promoting agent for patients suffering from narcolepsy or obstructive sleep apnea.
Noam had decided to dedicate his energy, expertise, and experience to help multitude of companies in bringing drugs to market and grow their business. He has been consulting pharmaceutical companies such as Actelion Pharmaceuticals, Omeros Corporation, Horizon Therapeutic, as well as technology companies in the space of R&D such as H1Insights.
Noam received his MD from the Sackler School of Medicine at the Tel Aviv University in 2003, and his MBA from the Foster School of Business at the University of Washington in 2007.
